The ALKS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALKS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALKS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALKS Detailed Price Forecast - CNN Money||View ALKS Detailed Summary - Google Finance|
|View ALKS Detailed Summary - Yahoo! Finance||View ALKS Stock Research & Analysis - Zacks.com|
|View ALKS Trends & Analysis - Trade-Ideas||View ALKS Major Holders - Barrons|
|View ALKS Call Transcripts - NASDAQ||View ALKS Breaking News & Analysis - Seeking Alpha|
|View ALKS Annual Report - CompanySpotlight.com||View ALKS OTC Short Report - OTCShortReport.com|
|View ALKS Fundamentals - TradeKing||View ALKS SEC Filings - Bar Chart|
|View Historical Prices for ALKS - The WSJ||View Performance/Total Return for ALKS - Morningstar|
|View the Analyst Estimates for ALKS - MarketWatch||View the Earnings History for ALKS - CNBC|
|View the ALKS Earnings - StockMarketWatch||View ALKS Buy or Sell Recommendations - MacroAxis|
|View the ALKS Bullish Patterns - American Bulls||View ALKS Short Pain Metrics - ShortPainBot.com|
|View ALKS Stock Mentions - StockTwits||View ALKS Stock Mentions - PennyStockTweets|
|View ALKS Stock Mentions - Twitter||View ALKS Investment Forum News - Investor Hub|
|View ALKS Stock Mentions - Yahoo! Message Board||View ALKS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALKS - SECform4.com||View Insider Transactions for ALKS - Insider Cow|
|View ALKS Major Holdings Summary - CNBC||View Insider Disclosure for ALKS - OTC Markets|
|View Insider Transactions for ALKS - Yahoo! Finance||View Institutional Holdings for ALKS - NASDAQ|
|View ALKS Stock Insight & Charts - FinViz.com||View ALKS Investment Charts - StockCharts.com|
|View ALKS Stock Overview & Charts - BarChart||View ALKS User Generated Charts - Trading View|
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
Posted on Friday August 02, 2019
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
Posted on Wednesday July 31, 2019
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Biogen Hedged Its Bet and Won Big
Posted on Tuesday July 30, 2019
The biotech had $4.3 billion in sales at risk.
DUBLIN and CAMBRIDGE, Mass., July 30, 2019 /PRNewswire/ -- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis (RRMS), compared to TECFIDERA® (dimethyl fumarate). Diroximel fumarate was statistically superior to dimethyl fumarate on the study's pre-specified primary endpoint, with patients treated with diroximel fumarate self-reporting significantly fewer days of key gastrointestinal (GI) symptoms with intensity scores ≥2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), as compared to dimethyl fumarate (p = 0.0003).